Riskpilot← Back to searchSign inGet full accessUroMedical Väst AB
ABActiveOrg 5590271846CarlanderskaHospital activities · NACE 8610Est. 201515 employees
Revenue 2025
SEK 53,4M
-13% vs 2024
EBITDA margin
7.8%
-42% vs 2024
Equity ratio
25.3%
Financial strength
Net profit 2025
SEK 0
+100% vs 2024
| Revenue | SEK 53,4M | -13% |
| EBITDA | SEK 4,2M | -42% |
| Net profit | SEK 0 | +100% |
| Total assets | SEK 22,1M | +27% |
| Equity | SEK 5,6M | -13% |
| Employees | 15 | — |
Legal name
UroMedical Väst AB
Org number
5590271846
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
21 september 2015
Share capital
SEK 50 000
Employees
15 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av ledamöterna Firman tecknas av suppleanten i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva urologmottagning vid Carlanderska sjukhuset.
Address
Carlanderska
Email
jonas@urol.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 42 780 | 52 317 | 56 699 | 55 209 | 60 331 | 62 783 | 68 403 | 61 136 | 53 418 |
| Staff expenses | — | — | — | — | — | — | — | — | −19 730 | −15 962 |
| EBITDA | 3 022 | 3 835 | 7 744 | 5 605 | 8 146 | 7 111 | 5 991 | 11 928 | 7 160 | 4 155 |
| Depreciation & amort. | −65 | −179 | −467 | −717 | −829 | −963 | −1 155 | −1 019 | −985 | −848 |
| EBIT | 2 957 | 3 656 | 7 277 | 4 888 | 7 317 | 6 148 | 4 836 | 10 909 | 6 175 | 3 307 |
| Net financials | 1 | 2 791 | 6 491 | −348 | −816 | −1 533 | −9 948 | 61 | −9 957 | 217 |
| Profit before tax | 2 958 | 6 447 | 13 768 | 4 540 | 3 239 | 3 340 | −1 501 | 0 | −3 781 | 0 |
| Tax | −659 | −774 | −1 565 | −977 | −697 | −690 | −679 | −0 | −712 | — |
| Net profit | 2 299 | 5 673 | 12 203 | 3 563 | 2 542 | 2 650 | −2 180 | 0 | −4 493 | 0 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 5 157 | 15 887 | 27 110 | 28 515 | 29 589 | 28 695 | 30 828 | 21 893 | 17 431 | 22 128 |
| Equity | 2 349 | 5 723 | 12 253 | 7 871 | 10 413 | 13 064 | 10 883 | 10 883 | 6 390 | 5 591 |
| Long-term debt | 0 | 4 434 | 7 200 | 0 | 0 | 0 | 0 | 0 | — | — |
| Short-term debt | 2 808 | 5 730 | 7 657 | 20 644 | 17 713 | 12 894 | 16 148 | 7 214 | 7 244 | 12 741 |
| Total debt | 2 808 | 10 164 | 14 857 | 20 644 | 17 713 | 12 894 | 16 148 | 7 214 | 7 244 | 12 741 |
EBITDA margin
7.8%
This company
15.8%
Market median
-51% vs market
20162025
Equity ratio
25.3%
This company
38.2%
Market median
-34% vs market
20162025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20162025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20162025
Asset turnover
2.41×
This company
1.12×
Market median
+115% vs market
20162025
Debt / equity
2.96×
This company
0.62×
Market median
-377% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BP Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
KK Chief Auditor | Chief Auditor | 2020 | — | — |
AM Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2024 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Deputy Board Member | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
UroMedical BidCo AB | Company | 100.0% | 100.0% | 2025 |
C-Medical Sverige AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ARMADA FUND V KY
UroMedical Väst AB Board members of UroMedical Väst AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Börje Patrik Lennart Andius | Chief Executive Officer | 0 companies |
| Karin Kristina Eriksson | Chief Auditor | 0 companies |
| Anna Maria Kristina Frånlund | Chief Executive Officer | 0 companies |
| Erik Rönnblad | Board of Directors | 0 companies |
| Thomas Haugen Skorpen | Board of Directors | 0 companies |
| Øyvind Bakke | Board of Directors | 0 companies |
| Gard Lauvsnes | Board of Directors | 0 companies |
| Fred Rosendal Helgesen | Chairman | 0 companies |
| Morten Henrik Greidung | Chairman | 0 companies |
| Patrik Bø Egeland | Chairman | 0 companies |
| Robert Gelmanovski | Chairman | 0 companies |
| Anna Ulrika Hansson | Board of Directors | 0 companies |
| Jan-Olof Wiklund | Deputy Board Member | 0 companies |
| Kurt Jonas Einar Hugosson | Board of Directors | 0 companies |
| Jonathan Kimber | Chairman | 0 companies |